128,603 Shares in Edwards Lifesciences Corporation $EW Acquired by Beacon Pointe Advisors LLC

Key Points

• Beacon Pointe Advisors acquired 128,603 Edwards Lifesciences shares worth approximately $11.6 million during the second quarter. Institutional investors collectively own 79.46% of the company.
• Edwards Lifesciences exceeded quarterly expectations, reporting $0.78 EPS versus the $0.74 consensus and $1.74 billion in revenue, up 13.6% year over year. The company issued third-quarter 2026 EPS guidance of $0.71–$0.77.
• Analysts maintain a generally positive outlook, with a “Moderate Buy” consensus and an average price target of $100.27, compared with the stock’s reported price of $90.19.

Beacon Pointe Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 128,603 shares of the medical research company's stock, valued at approximately $11,632,000.

A number of other large investors have also modified their holdings of the company. Pin Oak Investment Advisors Inc. purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $26,000. 49 Wealth Management LLC purchased a new position in shares of Edwards Lifesciences during the 2nd quarter worth $359,000. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in shares of Edwards Lifesciences during the 2nd quarter worth about $419,000. Orion Capital Management LLC purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $138,000. Finally, Glenview Trust Co purchased a new stake in Edwards Lifesciences in the 2nd quarter valued at about $11,026,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $90.19 on Friday. Edwards Lifesciences Corporation has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a fifty day simple moving average of $89.54 and a two-hundred day simple moving average of $85.03. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The company has a market cap of $51.93 billion, a price-to-earnings ratio of 51.83, a price-to-earnings-growth ratio of 2.36 and a beta of 0.85.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same period last year, the business posted $0.67 earnings per share. Edwards Lifesciences's revenue was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, VP Daniel J. Lippis sold 619 shares of the business's stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total transaction of $56,966.57. Following the completion of the transaction, the vice president owned 40,034 shares in the company, valued at approximately $3,684,329.02. The trade was a 1.52% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Annette Bruls sold 2,644 shares of the stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 4,501 shares of company stock valued at $408,213 in the last quarter. 0.31% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have weighed in on EW. Citigroup increased their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a "buy" rating in a research note on Wednesday, July 8th. Mizuho upped their price objective on shares of Edwards Lifesciences from $100.00 to $105.00 and gave the stock an "outperform" rating in a report on Wednesday, July 15th. Wall Street Zen cut shares of Edwards Lifesciences from a "buy" rating to a "hold" rating in a research report on Saturday, July 4th. Truist Financial lifted their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a "hold" rating in a report on Thursday, July 16th. Finally, TD Cowen reissued a "buy" rating on shares of Edwards Lifesciences in a research report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company's stock. According to MarketBeat, Edwards Lifesciences currently has an average rating of "Moderate Buy" and an average target price of $100.27.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.

Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corporation (NYSE:EW - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source